Core Insights - The article highlights the top and bottom AH share premium rates as of November 18, with Northeast Electric (00042) leading at 847.37% and Ningde Times (03750) at -7.82% [1][2][3] Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 847.37% with H-share priced at 0.285 HKD and A-share at 2.25 CNY [2] - Sinopec Oilfield Service (01033) follows with a premium rate of 296.15%, H-share at 0.780 HKD and A-share at 2.58 CNY [2] - Hongye Futures (03678) ranks third with a premium rate of 275.07%, H-share at 3.490 HKD and A-share at 10.93 CNY [2] Bottom AH Share Premium Rates - Ningde Times (03750) shows a negative premium rate of -7.82%, with H-share at 504.000 HKD and A-share at 387.89 CNY [3] - China Merchants Bank (03968) has a premium rate of -0.08%, H-share at 51.400 HKD and A-share at 42.88 CNY [3] - Heng Rui Pharmaceutical (01276) has a premium rate of 4.52%, with H-share at 70.800 HKD and A-share at 61.78 CNY [3] Top AH Share Deviation Values - Sinopec Oilfield Service (01033) leads in deviation value at 49.38% [1][4] - Zhejiang Shibao (01057) follows with a deviation value of 31.62% [1][4] - Beijing Jingcheng Machinery Electric (00187) has a deviation value of 28.48% [1][4] Bottom AH Share Deviation Values - Ganfeng Lithium (01772) has the lowest deviation value at -13.86% [1][5] - China Life (02628) follows with -12.23% [1][5] - CNOOC Services (02883) has a deviation value of -11.47% [1][5]

Core Viewpoint - Heng Rui Medicine (01276) has seen a stock price increase of nearly 3%, currently trading at 72.35 HKD, following the announcement of receiving clinical trial approval for its drug, Fumaric Acid Tegeline Injection, from the National Medical Products Administration [1] Group 1: Company Developments - On November 17, Heng Rui Medicine announced that it received the clinical trial approval notice for Fumaric Acid Tegeline Injection from the National Medical Products Administration [1] - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist, set to be approved for domestic market launch in January 2024, marking it as China's first independently developed Class 1 opioid analgesic innovation drug [1] - The company has invested approximately 200 million RMB in the research and development of Fumaric Acid Tegeline Injection to date [1] Group 2: Market Context - A similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, was approved for sale in the United States in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023, although no sales data has been reported yet [1]

Major Events - Shandong Xinhua Pharmaceutical Co., Ltd. received the approval notice for the listing application of fumaric acid vonoprazan chemical raw materials [1] - HeYue Pharmaceutical showcased long-term efficacy and safety data from the clinical III MANEUVER study of pitmiprazole at the CTOS 2025 conference [1] - China Software International partnered with Deep Open Hong and Yiswei Computing to build a new ecosystem for "open-source HarmonyOS + RISC-V" digital infrastructure [1] - China General Nuclear Power Corporation's Zhaoyuan Unit 1 is set to begin full construction [1] - Hengrui Medicine's fumaric acid teglutide injection received approval for clinical trials [1] - China National Nuclear Corporation signed an intention procurement agreement for cobalt-60 irradiation sources with the Brazilian National Nuclear Energy Commission [1] Operating Performance - China Railway Construction Corporation recently won several major projects with a total investment of 49.629 billion yuan [1] - Geely Automobile reported a net profit of 3.82 billion yuan for the third quarter, a year-on-year increase of 59% [1] - China Resources Power's subsidiary power plants achieved a cumulative electricity sales volume of 185 million megawatt-hours in the first ten months, a year-on-year increase of 6.5% [1] - Leap Motor reported a net profit of 150 million yuan for the third quarter, maintaining the top sales position among new force brands in China for eight consecutive months [1] - Huazhu Group's net profit attributable to shareholders for the third quarter was 1.5 billion yuan, a year-on-year growth of 15.4% [1] - Air China saw a year-on-year increase of 8.7% in passenger turnover in October [1] - China Eastern Airlines reported a year-on-year increase of 10.58% in passenger turnover in October [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Fumaric Acid Tegeline Injection, marking a significant step in the development of China's first independently developed Class 1 opioid analgesic [1] Group 1: Product Development - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist [1] - The product is expected to be launched in China in January 2024 [1] - The company has invested approximately 200 million yuan in the research and development of this project [1] Group 2: Market Context - Oliceridine, a similar product developed by Trevena, was approved for sale in the United States in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023 [1] - No sales data for Oliceridine in China has been reported as of now [1]

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries have been granted clinical trial approval for HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Adalimumab injection, Bevacizumab injection, SHR-A2102 for injection, Famitinib malate capsules, and Darsylis sulfate tablets [1] - The approved clinical trials are set to commence in the near future, reflecting the company's ongoing commitment to expanding its product offerings [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Fumaric Acid Tegilide Injection, which will be conducted soon [1] Group 1: Drug Information - Drug Name: Fumaric Acid Tegilide Injection [1] - Dosage Form: Injection [1] - Application Matter: Clinical Trial [1] - Acceptance Numbers: CXHL2500912, CXHL2500913 [1] Group 2: Approval Details - Approval Conclusion: The clinical trial application for Fumaric Acid Tegilide Injection, accepted on August 28, 2025, meets the requirements for drug registration [1] - Purpose of Clinical Trial: To conduct clinical trials for pain relief in mechanically ventilated patients in intensive care [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6209 capsules and HRS-2189 tablets, which will be conducted in conjunction with aromatase inhibitors for breast cancer treatment [1] Group 1: Regulatory Approval - The company and its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., have been granted the Clinical Trial Approval Notice for HRS-6209 and HRS-2189 [1] - The approval is based on the review under the Drug Administration Law of the People's Republic of China, confirming that the drugs meet the registration requirements [1] Group 2: Clinical Trial Details - The clinical trials for HRS-6209 will be conducted in combination with HRS-2189 and aromatase inhibitors specifically for breast cancer [1] - The acceptance date for the application was August 13, 2025, indicating a timeline for the development of these drugs [1]

Core Viewpoint - Recently, Jiangsu Hengrui Medicine Co., Ltd. and its subsidiaries received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in their drug development pipeline [1] Group 1: Clinical Trial Approvals - The company has received approval for clinical trials of HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Abediteran injection, Bevacizumab injection, SHR-A2102 injection, Apalutamide capsules, and Darsylis sulfate tablets [1] - The approval is based on compliance with the relevant drug registration requirements as per the Drug Administration Law of the People's Republic of China [1] - The specific study includes a Phase I/II trial to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with anti-tumor drugs in subjects with solid tumors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年11月17日 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年11月17日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-1 ...